Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
In preclinical studies, Tinostamustine has been shown to improve access to the DNA strands within cancer cells, damaging the cancer cells, DNA and preventing it from repairing itself.
| SparkCures ID | 225 |
|---|---|
| Developed By | Mundipharma EDO GmbH |
| Generic Name | Tinostamustine |
| Additional Names | EDO-S101 |
| Treatment Classifications |
There are no resources, links or videos to display for this treatment.
SparkCures is working closely with Mundipharma EDO GmbH to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners